BioCentury | Sep 14, 2018
Finance

Solidifying Atreca’s repertoire

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic. An undisclosed,...
BC Extra | Jun 5, 2018
Financial News

Tricida files for $150M IPO

Renal disease company Tricida Inc. (South San Francisco, Calif.) filed to raise up to $150 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan and Cowen. In 2H19, Tricida plans to submit...
BC Extra | May 15, 2017
Company News

Akebia, Vifor in distribution deal for vadadustat

Akebia Therapeutics Inc. (NASDAQ:AKBA) was up $1.87 (14%) to $14.77 in after-hours trading after it said it granted Vifor Pharma Group (SIX:VIFN) exclusive U.S. distribution rights to vadadustat (formerly AKB-6548) to treat anemia associated with...
BC Week In Review | May 11, 2017
Clinical News

Daiichi starts Phase III HEART-FID trial of iron therapy for heart failure

American Regent Inc. began the Phase III HEART-FID trial of ferric carboxymaltose (Z-213) to treat heart failure with iron deficiency and reduced ejection fraction in about 3,014 patients. The double-blind, U.S. trial will evaluate incidence...
BC Week In Review | Apr 13, 2017
Financial News

Galenica financial update

The Galenica Group spun out its pharmacy and consumer healthcare business into Galenica Santé Ltd. (SIX:GALE) via an IPO on the SIX Swiss Exchange. The remaining Galenica Group business is to be renamed Vifor Pharma...
BC Extra | Apr 7, 2017
Financial News

Galenica becoming Vifor after Santé spinout

The Galenica Group spun out its pharmacy and consumer healthcare business into Galenica Santé (SIX:GALE) via an IPO on the SIX Swiss Exchange. The remaining Galenica Group business is to be renamed Vifor Pharma Group...
BC Extra | Mar 17, 2017
Company News

FDA issues second CRL for AZ's hyperkalemia candidate

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it received a second complete response letter from FDA for ZS-9 , its candidate to treat hyperkalemia. The pharma said the CRL followed an FDA inspection of the ZS-9 manufacturing facility...
BC Extra | Feb 24, 2017
Financial News

China's Ally Bridge adds European companies to portfolio

Hong Kong's Ally Bridge Group continued to find deals in Europe, announcing it has added Austria's Nabriva Therapeutics AG (NASDAQ:NBRV) and Switzerland's Galenica Ltd. (SIX:GALN) to its portfolio. Ally Bridge declined to disclose specifics but...
BC Week In Review | Feb 17, 2017
Company News

ChemoCentryx, Galenica deal

ChemoCentryx and Galenica’s Vifor Pharma company added rights in Asia and the Middle East to a 2016 licensing deal to commercialize avacopan (CCX168). Vifor now has rights to the compound worldwide outside of the U.S....
BC Innovations | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
Items per page:
1 - 10 of 126
BioCentury | Sep 14, 2018
Finance

Solidifying Atreca’s repertoire

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic. An undisclosed,...
BC Extra | Jun 5, 2018
Financial News

Tricida files for $150M IPO

Renal disease company Tricida Inc. (South San Francisco, Calif.) filed to raise up to $150 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan and Cowen. In 2H19, Tricida plans to submit...
BC Extra | May 15, 2017
Company News

Akebia, Vifor in distribution deal for vadadustat

Akebia Therapeutics Inc. (NASDAQ:AKBA) was up $1.87 (14%) to $14.77 in after-hours trading after it said it granted Vifor Pharma Group (SIX:VIFN) exclusive U.S. distribution rights to vadadustat (formerly AKB-6548) to treat anemia associated with...
BC Week In Review | May 11, 2017
Clinical News

Daiichi starts Phase III HEART-FID trial of iron therapy for heart failure

American Regent Inc. began the Phase III HEART-FID trial of ferric carboxymaltose (Z-213) to treat heart failure with iron deficiency and reduced ejection fraction in about 3,014 patients. The double-blind, U.S. trial will evaluate incidence...
BC Week In Review | Apr 13, 2017
Financial News

Galenica financial update

The Galenica Group spun out its pharmacy and consumer healthcare business into Galenica Santé Ltd. (SIX:GALE) via an IPO on the SIX Swiss Exchange. The remaining Galenica Group business is to be renamed Vifor Pharma...
BC Extra | Apr 7, 2017
Financial News

Galenica becoming Vifor after Santé spinout

The Galenica Group spun out its pharmacy and consumer healthcare business into Galenica Santé (SIX:GALE) via an IPO on the SIX Swiss Exchange. The remaining Galenica Group business is to be renamed Vifor Pharma Group...
BC Extra | Mar 17, 2017
Company News

FDA issues second CRL for AZ's hyperkalemia candidate

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it received a second complete response letter from FDA for ZS-9 , its candidate to treat hyperkalemia. The pharma said the CRL followed an FDA inspection of the ZS-9 manufacturing facility...
BC Extra | Feb 24, 2017
Financial News

China's Ally Bridge adds European companies to portfolio

Hong Kong's Ally Bridge Group continued to find deals in Europe, announcing it has added Austria's Nabriva Therapeutics AG (NASDAQ:NBRV) and Switzerland's Galenica Ltd. (SIX:GALN) to its portfolio. Ally Bridge declined to disclose specifics but...
BC Week In Review | Feb 17, 2017
Company News

ChemoCentryx, Galenica deal

ChemoCentryx and Galenica’s Vifor Pharma company added rights in Asia and the Middle East to a 2016 licensing deal to commercialize avacopan (CCX168). Vifor now has rights to the compound worldwide outside of the U.S....
BC Innovations | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
Items per page:
1 - 10 of 126